First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. - Wermke M; Holderried TAW; Luke JJ; Morris VK; Alsdorf WH; Wetzko K; Andersson BS; Wistuba II; Parra ER; Hossain MB; Grund-Gröschke S; Aslan K; et al. (Journal for immunotherapy of cancer, 2024)